Skip to content

Study about the comprehensive therapy of TCM intervention in the whole course of diabetic nephropathy

Study about the comprehensive therapy of TCM intervention in the whole course of diabetic nephropathy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017996
Enrollment
Unknown
Registered
2018-08-25
Start date
2008-01-01
Completion date
Unknown
Last updated
2018-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabeitc nephropathy

Interventions

Group 2:Basic treatment of hypoglycemic medicine, hypotensive medicine and dietary treatment plus irbesartan
Group 1:Basic treatment of hypoglycemic medicine, hypotensive medicine and dietary treatment plus TCM treatment based on syndrome differentiation

Sponsors

Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Serum creatinine (Scr) was stable below 265umol/L for 3 months; 2. The diastolic blood pressure was kept stable below 90mmHg after hypotension, the blood glucose was basically controlled, and the glycosylated hemoglobin (HbA1c) was controlled below 7%; 3. TCM syndrome differentiation is Yin deficiency type (including manifestations of Yin deficiency and Qi deficiency), or Yang deficiency type (including manifestations of Yang deficiency and Qi deficiency), or Yin and Yang deficiency type (including manifestations of Yin deficiency, Yang deficiency and Qi deficiency), or blood stasis obstructing collateral vessel type, or dampness turbidity type.

Exclusion criteria

Exclusion criteria: 1. Intractable edema; 2. Urine protein > 10g/24h, serum albumin < 25g/L; 3. renovascular hypertension; 4. Patients have emergency and severe cases within 6 months, which like malignant hypertension, myocardial infarction, cerebrovascular accident, diabetic ketoacidosis and so on; 5. Combination with congestive heart failure of level I-IV; 6. Patients who are not suitable for this intervention, such as patients with cancer, pregnancy and patients being allergic to intervening drugs.

Design outcomes

Primary

MeasureTime frame
endpoint event;

Secondary

MeasureTime frame
24h urinal protein;urinary albumin excretion rate;serum creatinine;Glomerular filtration rate;Scores of TCM syndromes;Scores of QOL;

Countries

China

Contacts

Public ContactJinxi Zhao

Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine

zhaojinximd@126.com+86 010 84013361

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026